Minor effects of the Citrus flavonoids naringin, naringenin and quercetin, on the pharmacokinetics of doxorubicin in rats

Pharmazie

Volumn 66, Issue 6, 2011, Pages 424-429

  Park, Hyun Seo ^a   Oh, J U Hee ^a   Lee, Joo Hyun ^a   Lee, Young Joo ^a  

^a Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AURANTIIN; CALCEIN; CYCLOSPORIN A; DOXORUBICIN; DRUG METABOLITE; GLYCOPROTEIN P; NARINGENIN; QUERCETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; KIDNEY CLEARANCE; MALE; NONHUMAN; RAT; TISSUE DISTRIBUTION; URINARY EXCRETION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRUS; CYCLOSPORINE; DOXORUBICIN; DRUG INTERACTIONS; FLAVANONES; INFUSIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; P-GLYCOPROTEIN; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 79959921537     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0857     Document Type: Article

References (41)

1. Ali MM, Agha FG, El-Sammad NM, Hassan SK (2009) Modulation of anticancer drug-induced P-glycoprotein expression by naringin. Z Naturforsch C 64: 109-116.
2. Ameer B, Weintraub RA, Johnson JV, Yost RA, Rouseff RL (1996) Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther 60: 34-40. (Pubitemid 26279218)
3. Bailey DG (2010) Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol 70: 645-655.
4. Bakos E, Evers R, Szakacs G, Tusnady GE, Welker E, Szabo K, de Haas M, van Deemter L, Borst P, Varadi A, Sarkadi B (1998) Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem 273: 32167-32175. (Pubitemid 29177162)
5. Bansal T, Jaggi M, Khar RK Talegaonkar S (2009) Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12: 46-78.
6. Boumendjel A, Di Pietro A, Dumontet C, Barron D (2002) Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev 22: 512-529.
7. Bredsdorff L, Nielsen IL, Rasmussen SE, Cornett C, Barron D, Bouisset F, Offord E, Williamson G (2010) Absorption, conjugation and excretion of the flavanones, naringenin and hesperetin from alpha-rhamnosidase-treated orange juice in human subjects. Br J Nutr 103: 1602-1609.
8. Chabane MN, Ahmad AA, Peluso J, Muller CD, Ubeaud-Séquier G (2009) Quercetin and naringenin transport across human intestinal Caco-2 cells. J Pharm Pharmacol 61: 1473-1483.
9. Chieli E, Romiti N, Cervelli F, Tongiani R (1995) Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci 57: 1741-1751.
10. Choi JS, Kang KW (2008) Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin. Arch Pharm Res 31: 1631-1636.
11. Critchfield JW, Welsh CJ, Phang JM, Yeh GC (1994) Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 48: 1437-1445.
12. Dahan A, Amidon GL (2009) Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res 26: 883-892.
13. de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V (2008) Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. J Agric Food Chem 56: 4840-4845. (Pubitemid 351999419)
14. Dresser GK, Kim RB, Bailey DG (2005) Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 77: 170-177. (Pubitemid 40269132)
15. Erlund I, Meririnne E, Alfthan G, Aro A (2001) Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 131: 235-241. (Pubitemid 32115362)
16. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC (2007) A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 45: 2179-2205.
17. Holló Z, Homolya L, Davis CW, Sarkadi B (1994) Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochimica et Biophysica Acta (BBA) - Biomembranes 1191: 384-388. (Pubitemid 24183562)
18. Kleeberger L, Rottinger EM (1993) Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin A cytotoxicity for Chinese hamster ovary cells. Cancer Chemother Pharmacol 33: 144-148. (Pubitemid 23325415)
19. Li X, Choi JS (2009) Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats. Anticancer Res 29: 1411-1415.
20. Lim SC, Choi JS (2006) Effects of naringin on the pharmacokinetics of intravenous paclitaxel in rats. Biopharm Drug Dispos 27: 443-447.
21. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99: 2545-2553.
22. Mandery K, Bujok K, Schmidt I, Keiser M, Siegmund W, Balk B, König J, Fromm MF, Glaeser H (2010) Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol 80: 1746-1753.
23. Morjani H, Madoulet C (2010) Immunosuppressors as multidrug resistance reversal agents. Methods Mol Biol 596: 433-446.
24. Murota K, Terao J (2003) Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch Biochem Biophys 417: 12-17. (Pubitemid 36960043)
25. Nakatsuma A, Fukami T, Suzuki T, Furuishi T, Tomono K, Hidaka S (2010) Effects of kaempferol on the mechanisms of drug resistance in the human glioblastoma cell line T98G. Pharmazie 65: 379-383.
26. Peng HW, Huang YT, Chen CF, Tsai TH (1998) Glucuronidation of naringenin in rats. Planta Med 64: 779.
27. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G, Piantelli M, Bussa S, Rumi C, Cianfriglia M et al. (1994) Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34: 459-464. (Pubitemid 24306043)
28. Shapiro AB, Ling V (1997) Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 53: 587-596. (Pubitemid 27149553)
29. Shen J, Zhang W, Wu J, Zhu Y (2008) The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells. Int J Hyperthermia 24: 151-159. (Pubitemid 351279955)
30. Shimizu A, Miyoshi M, Sugie M, Ueyama J, Yamaguchi T, Sasaki T, Takagi K, Jin M, Miyamoto K, Tsuji A, Hasegawa T (2004) Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats. Eur J Pharmacol 501: 151-159. (Pubitemid 39298948)
31. Tavoloni N, Guarino AM (1980a) Biliary and urinary excretion of adriamycin in anesthetized rats. Pharmacology 20: 256-267. (Pubitemid 10100205)
32. Tavoloni N, Guarino AM (1980b) Disposition and metabolism of adriamycin in the rat. Pharmacology 21: 244-255. (Pubitemid 10048437)
33. Tian R, Koyabu N, Takanaga H, Matsuo H, Ohtani H, Sawada Y (2002) Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 19: 802-809. (Pubitemid 34686739)
34. van Asperen J, van Tellingen O, Beijnen JH (2000) The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 28: 264-267.
35. van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH (1999) Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 79: 108-113. (Pubitemid 28566934)
36. van derWoude H, Boersma MG, Vervoort J Rietjens IM (2004) Identification of 14 quercetin phase II mono- and mixed conjugates and their formation by rat and human phase II in vitro model systems. Chem Res Toxicol 17: 1520-1530.
37. Walle T, Wen X, Walle UK (2007) Improving metabolic stability of cancer chemoprotective polyphenols. Expert Opin Drug Metab Toxicol 3: 379-388. (Pubitemid 47316030)
38. Wanwimolruk S, Marquez PV (2006) Variations in content of active ingredients causing drug interactions in grapefruit juice products sold in California. Drug Metabol Drug Interact 21: 233-243. (Pubitemid 43971440)
39. Zhang FY, Du GJ, Zhang L, Zhang CL, Lu WL, Liang W (2009) Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharm Res 26: 914-925.
40. Zhang S, Morris ME (2003) Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304: 1258-1267. (Pubitemid 36254439)
41. Zhou S, Lim LY, Chowbay B (2004) Herbal modulation of P-glycoprotein. Drug Metab Rev 36: 57-104. (Pubitemid 38387835)